8/9/2010

DUSA Pharmaceuticals plans to end a midstage study of its Levulan photodynamic therapy, after the FDA declined to give orphan-drug designation to the treatment. The drug is used to prevent skin cancer in organ transplant patients.

Full Story:
Reuters

Related Summaries